Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Theravance Biopharma, Inc.NASDAQ: TBPH

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 51.28M shares rose 3.2% year over year, in line with the +3.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.

Context

  • Weighted avg shares increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +3.2% holds above the trailing-twelve-month pace of +3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
51.28M+0.8% QoQ
Last fiscal yearDec 2025
50.32M+3.0% YoY
LTMMar 2026
50.71M+3.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.2%——
1 year+3.0%——
3-year CAGR-11.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
50.32M USD
Year-over-year change
+3.0%
4-year CAGR
-7.7%

Weighted Avg Shares vs competitors

How TBPH compares with its peers on the latest reported figures

  • TBPH's LTM Mar 2026 weighted avg shares of 50.71M shares is the 7th highest of the 9 companies compared; the peer median is 78.9M shares.
  • Its year-over-year change of +3.1% is the 5th highest of 9, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of -11.9% compares with a peer median of +14.5%.
TBPH Competitors Peer median
Weighted Avg Shares for TBPH and competitors
Company Period LTM YoY 3-year CAGR
GERNGeron CorporationLTM Mar 2026667.45M +1.6%+20.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
REPLReplimune Group, Inc.LTM Dec 202589.05M +21.7%+15.6%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202673.92M -0.4%+20.7%
TYRATyra Biosciences, Inc.LTM Mar 202660.14M +2.0%+12.5%
TBPHTheravance Biopharma, Inc.LTM Mar 202650.71M +3.1%-11.9%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
LENZLENZ Therapeutics, Inc.LTM Mar 202629.76M +10.4%+54.3%
Peer median (excluding TBPH) 78.9M+6.8%+14.5%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.